Press / Medias

LNC secure 6,5 million euros funding for microbiota-focused strategy – looking to IPO

Oct 2, 2017

LNC Therapeutics has raised €6.5m in a Series C funding round as the company announces a new chief science officer and steps up an ‘ambitious’ microbiota-orientated strategy that it hopes will drive an IPO by the end of 2019.

In the same category

Press / Medias

EMA & FDA Apply a Similar Mindset When Providing Scientific Advice For Live Biotherapeutic...

Sep 13, 2021

more +
Press / Medias

Bordeaux : un traitement prometteur contre l’obésité développé à base d’une...

Jun 16, 2021

more +
Press / Medias

Le pari gagnant du microbiome

May 24, 2021

more +

YSOPIA Bioscience © 2021 - all rights reserved terms and conditions